IDBS acquisition extends lifecycle management capabilities 

Global life sciences software company IDBS has acquired biopharmaceutical manufacturing data management and analytics software developer Skyland Analytics, in a move that will create the first BioPharma Lifecycle Management (BPLM) offering that supports therapies from early development through commercial manufacturing.  


More than half of biopharma organisations1 have process data and knowledge on paper, spreadsheets and disparate systems, creating quality risks and dramatically increasing the time and cost of bringing new therapies to market. Skyland PIMS is used to manage and contextualise data across the clinical and commercial production phases of the biopharma lifecycle, dramatically accelerating time to insight. 

Official comments 

“Skyland Analytics’ powerful combination of deep domain knowledge and innovative software provide a new level of insight across the biopharma lifecycle,” said Christian Marcazzo, Vice President & General Manager of IDBS. “For the first time, process data and knowledge can be efficiently integrated throughout all stages of the lifecycle and the complex network of internal and external teams, sites, and partners so prevalent in today’s manufacturing infrastructure. We are excited to help our customers accelerate new therapeutics to market by enabling a novel level of speed, agility and insight.” 

Robert Di Scipio, founder and CEO of Skyland Analytics, said: “By bringing together IDBS Polar and Skyland PIMS we are creating a uniquely differentiated offering that helps surface the data and insights needed to accelerate drugs to market. By streamlining technology transfer, creating a persistent, dynamic data backbone throughout the product lifecycle and improving process understanding, these solutions will help in the design and monitoring of more scalable, robust and higher yielding processes. This is a significant milestone in the mission to reduce the time, cost and risk of bringing new therapies to market.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free